This inventor holds 7 USPTO granted patents and 11 published patent applications and 2 EPO patents. Top assignee: Asterion, Inc.. Active years: 2008-2013.
Location History:
- Sheffield, GB (2008 - 2012)
- Chesterfield, GB (2012 - 2013)
Company Filing History:
Years Active: 2008-2013
Title: Jon Sayers - Innovator in Growth Hormone Fusion Proteins
Introduction
Jon Sayers is a prominent inventor based in Sheffield, GB. He has made significant contributions to the field of biotechnology, particularly in the development of growth hormone fusion proteins. With a total of 7 patents to his name, Sayers is recognized for his innovative approaches to addressing growth hormone deficiencies.
Latest Patents
Sayers' latest patents focus on growth hormone fusion proteins that exhibit increased in vivo stability and activity. These patents disclose nucleic acid molecules encoding the fusion proteins and methods for treating growth hormone deficiency using these innovative solutions. The growth hormone fusion proteins consist of human growth hormone (GH) covalently linked to the extracellular domain of the Growth Hormone Receptor (GHR). This linkage can occur either as a direct in-frame translational fusion or through a flexible peptide linker. The resulting GH/GHR fusion proteins demonstrate exceptional pharmacokinetics and act as potent growth hormone receptor agonists. Notably, these fusion proteins form head-to-tail dimers, enhancing their therapeutic potential.
Career Highlights
Jon Sayers is currently associated with Asterion, Inc., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biotechnology sector, particularly in the realm of growth hormone therapies.
Collaborations
Sayers has collaborated with notable colleagues, including Richard Ross and Peter Artymiuk. These partnerships have contributed to the success of his research and the development of innovative solutions in the field.
Conclusion
Jon Sayers is a distinguished inventor whose work on growth hormone fusion proteins has the potential to transform treatment options for individuals with growth hormone deficiencies. His innovative contributions and collaborations underscore his importance in the biotechnology industry.